{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:24:11Z","timestamp":1757618651667,"version":"3.44.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11348-w","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T04:57:09Z","timestamp":1752296229000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug resistance of Mycobacterium tuberculosis to linezolid and delamanid: a case report from Bukavu, Democratic Republic of Congo"],"prefix":"10.1186","volume":"25","author":[{"given":"Bertin C.","family":"Bisimwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esto","family":"Bahizire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Kiselinova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9ry","family":"Byela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Claude S.","family":"Ngabonziza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Hakizayezu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Docteur","family":"Runyambo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conor J.","family":"Meehan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wim","family":"Mulders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Cuella-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leen","family":"Rigouts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freddy","family":"Birembano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Callens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bouke C.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Kaswa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"issue":"10","key":"11348_CR1","first-page":"1","volume":"61","author":"B Matthew","year":"2017","unstructured":"Matthew B, McNeil DD, Dennison, Catherine D. Shelton TP. crossm in vitro isolation and characterization of Oxazolidinone-Resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2017;61(10):1\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"11348_CR2","first-page":"1","volume":"62","author":"W Zhaojing Zong","year":"2018","unstructured":"Zhaojing Zong W, Jing J, Shi Shu\u2019an, Wen T, Zhang F, Huo Y, Shang Q, Liang, Hairong Huang YP. Comparison of in vitro activity and MIC distributions between the novel Oxazolidinone delpazolid and linezolid against Multidrug-Resistant and extensively Drug-Resistant Mycobacterium tuberculosis in China. Antimicrob Agents Chemother. 2018;62(8):1\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"11348_CR3","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/jac\/dkx094","volume":"72","author":"DV Zimenkov","year":"2017","unstructured":"Zimenkov DV, Nosova EY, Kulagina EV, Antonova OV, Arslanbaeva LR, Isakova AI, et al. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region. J Antimicrob Chemother. 2017;72(7):1901\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"11348_CR4","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/jac\/dkx506","volume":"73","author":"N Dookie","year":"2018","unstructured":"Dookie N, Rambaran S, Padayatchi N, Mahomed S, Naidoo K. Evolution of drug resistance in Mycobacterium tuberculosis: A review on the molecular determinants of resistance and implications for personalized care. J Antimicrob Chemother. 2018;73(5):1138\u201351.","journal-title":"J Antimicrob Chemother"},{"issue":"05","key":"11348_CR5","first-page":"1","volume":"17","author":"R\u00e9publique D\u00e9mocratique du Congo Minist\u00e8re de la Sant\u00e9 Publique","year":"2019","unstructured":"Programme National de lutte contre la tuberculose (PNLT). Guide TB-PR Revis\u00e9. Minist\u00e8re la sant\u00e9 publique. 2019;17(05):1-84.","journal-title":"Programme National de Lutte contre la Tuberculose (PNT)"},{"key":"11348_CR6","unstructured":"World Health Organization. Technical Report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine) [Internet]. 2021. Licence: CC BY-NC-SA 3.0 IGO. Available from: https:\/\/www.who.int\/publications\/i\/item\/technical-report-on-critical-concentrations-for-drugsusceptibility-testing-of-isoniazid-and-therifamycins-(rifampicin-rifabutin-and-rifapentine)."},{"key":"11348_CR7","doi-asserted-by":"crossref","unstructured":"Ardizzoni E, Ariza E, Mulengwa D, Mpala Q, de la Tour R, Maphalala G et al. Thin-layer-agar-based direct phenotypic drug susceptibility testing on sputum in Eswatini rapidly detects mycobacterium tuberculosis growth and rifampicin resistance otherwise missed by WHO-endorsed diagnostic tests. Antimicrob Agents Chemother. 2021;65(6):e02263-20.","DOI":"10.1128\/AAC.02263-20"},{"issue":"12","key":"11348_CR8","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1093\/cid\/ciaa755","volume":"71","author":"TVA Nguyen","year":"2020","unstructured":"Nguyen TVA, Anthony RM, Cao TTH, Ba\u00f1uls AL, Nguyen VAT, Vu DH, et al. Delamanid resistance: update and clinical management. Clin Infect Dis. 2020;71(12):3252\u20139.","journal-title":"Clin Infect Dis"},{"key":"11348_CR9","doi-asserted-by":"crossref","unstructured":"Lempens P, Meehan CJ, Vandelannoote K, Fissette K, De Rijk P, Van Deun A et al. Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations. Sci Rep. 2018;8(1):1-9.","DOI":"10.1038\/s41598-018-21378-x"},{"issue":"12","key":"11348_CR10","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1101\/gr.210641.116","volume":"26","author":"D Kim","year":"2016","unstructured":"Kim D, Song L, Breitwieser FP, Salzberg SL, Centrifuge. Rapid and sensitive classification of metagenomic sequences. Genome Res. 2016;26(12):1721\u20139.","journal-title":"Genome Res"},{"issue":"1","key":"11348_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-019-0650-x","volume":"11","author":"JE Phelan","year":"2019","unstructured":"Phelan JE, O\u2019Sullivan DM, Machado D, Ramos J, Oppong YEA, Campino S, et al. Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs. Genome Med. 2019;11(1):1\u20137.","journal-title":"Genome Med"},{"key":"11348_CR12","unstructured":"World Health Organization. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. 2023. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240028173."},{"issue":"3","key":"11348_CR13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.5588\/ijtld.17.0837","volume":"23","author":"RH Berhanu","year":"2019","unstructured":"Berhanu RH, Schnippel K, Kularatne R, Firnhaber C, Jacobson KR, Horsburgh CR, et al. Discordant rifampicin susceptibility results are associated with Xpert\u00ae MTB\/RIF probe B and probe binding delay. Int J Tuberc Lung Dis. 2019;23(3):358\u201362.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"11348_CR14","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1016\/S2666-5247(20)30007-0","volume":"1","author":"JCS Ngabonziza","year":"2020","unstructured":"Ngabonziza JCS, Decroo T, Migambi P, Habimana YM, Van Deun A, Meehan CJ, et al. Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB\/RIF results: a prospective observational study in Rwanda. The Lancet Microbe. 2020;1(2):e74-83. Available from:\u00a0https:\/\/doi.org\/10.1016\/S2666-5247(20)30007-0.","journal-title":"The Lancet Microbe"},{"key":"11348_CR15","doi-asserted-by":"crossref","unstructured":"Cuella-Martin I, Hakizayezu Fran\u00e7ois, Ahmed A, Runyambo D, Keysers J, De Rijk WB, Mulders W, Mitchell EMH, Decroo T, Habimana YM, Migambi P, Muvunyi CM, de Jong BC. L. Rigouts JC. N. High rates of false rifampicin resistance in paucibacillary tuberculosis patients by Xpert MTB\/RIF ultra. Lancet. 2024;1\u201319.","DOI":"10.2139\/ssrn.4922920"},{"issue":"9","key":"11348_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0185105","volume":"12","author":"BM Musa","year":"2017","unstructured":"Musa BM, Adamu AL, Galadanci NA, Zubayr B, Odoh CN, Aliyu MH. Trends in prevalence of multi drug resistant tuberculosis in sub-Saharan africa: A systematic review and meta-analysis. PLoS ONE. 2017;12(9):1\u201315.","journal-title":"PLoS ONE"},{"key":"11348_CR17","doi-asserted-by":"publisher","unstructured":"G\u00fcnther G, Guglielmetti L, Leu C, Lange C, van Leth F. TBnet. Cost and availability of drugs and treatment regimens and availability of drug resistance testing for tuberculosis in Europe. medRxiv. 2022;2022.02.15.22271006. Available from: https:\/\/doi.org\/10.1101\/2022.02.15.22271006.","DOI":"10.1101\/2022.02.15.22271006"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11348-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11348-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11348-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T06:12:21Z","timestamp":1757225541000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11348-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11348"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11348-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2025,7,12]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was received from the Institutional Ethics Committee of the Universit\u00e9 Catholique de Bukavu (reference number UCB\/CIES\/NC\/015\/2022). The patient voluntarily agreed to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient gave written informed consent for the publication of the data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"913"}}